X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home IPR Data Management

Electronic Patient Record provider PatientSource to offer slimmed down version of their software in response to Coronavirus pandemic

Content Team by Content Team
8th April 2020
in IPR Data Management, Press Statements
Electronic Patient Record provider PatientSource to offer slimmed down version of their software in response to Coronavirus pandemic

PatientSource has announced that it will be offering an adapted version of its Electronic Patient Record (EPR) software to healthcare organisations across the globe, completely free of charge with minimal cloud hosting costs, to help combat the Coronavirus pandemic.

With the priority to ease the burden on healthcare services now reaching critical levels, PatientSource is offering a ‘slimmed down’ version of its software, which can be installed and ready to go within as little as an hour, in a move to keep a ‘digital eye’ over the ever-increasing number of COVID-19 patients.

Founded by a practising NHS doctor and recognised as a ‘leading innovator’ by the Department of International Trade, PatientSource offers a cloud-based interoperable patient record system with an intuitive interface, designed for use on the frontline of care. The clinician-designed solution works cross-platform on any device with a web browser – desktops, laptops, tablets and smartphones. The company has an international footprint, with clients in the NHS and private sector.

The adapted version of the PatientSource software will feature a cloud-based electronic observation module complete with patient trackers and ward whiteboard tools that are attuned to COVID-19 patients, and will be able to quickly identify the most critical, frail or deteriorating patients in a challenging setting.

Dr Michael Brooks, Chief Medical Officer and Co-Founder of PatientSource, said: “COVID-19 is a virus that spreads quickly and causes an appreciable minority of people to need hospital care. Put those two figures together, and you get a virus that will easily overwhelm any country’s healthcare system. Hospitals across the globe are going to be saturated and will struggle to cope.

“PatientSource brings case tracking, clinical noting, vital signs, test requests and results, team messaging, and prescribing together in one place. A doctor or nurse can walk onto a ward with just one tablet and access everything they need.”

“Our PatientSource COVID-19 tracker will show you which affected patients are in your hospital or ward, what their latest vitals are, the plans for escalation, and who the expected incoming cases are in real-time. This allows you to identify the patients who need oxygen bays and the patients who need critical care input, allowing you to allocate limited resources to those who need them quickly.”

Recent announcements from the Department of Health and Social Care have revealed that they will soon call upon private hospitals and possibly requisition hotels to help deal with the ever-growing number of NHS patients, meaning that resources are to be spread thinly and widely. PatientSource hopes that the capabilities of its EPR solution in providing digital oversight over a rapidly expanding patient cohort will support overstretched medical services both in the UK and across the globe.

Its experience of working across both sectors and the interoperable capabilities of its EPR solution will help providers to maximise the efficiency of their available resources by applying them appropriately to the most critical patients.

Dr Brooks added: “As an Emergency Department Clinician I acutely understand the challenges faced by my peers in caring for large numbers of patients with limited staff resources. This offer aligns to my founding ethos for PatientSource of better patient care; I hope we can help.”

About PatientSource
PatientSource provides an Electronic Medical Record (EMR) solution which is disrupting the healthcare market. The company has a global footprint and track record of success working with the NHS and private sector. Founded by practising clinicians, we are empowering healthcare organisations across the world to move away from paper-based records. Unique in its offering to the global healthcare market, this affordable EMR promises greater user experience and the safer, more efficient delivery of care.

Previous Post

Virgin Atlantic and CEVA in medical equipment relief flight

Next Post

Incyte Announces Plans to Initiate a Phase 3 Clinical Trial of Ruxolitinib as a Treatment for Patients with COVID-19 Associated Cytokine Storm

Related Posts

Avadel Pharmaceuticals Receives
Drug Development

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

9th June 2025
ACHEMA
Middle East and South Asia

ACHEMA Middle East to Debut in Riyadh in 2026 Trade Show

9th May 2025
Press Statements

APM Steam Highlights Comprehensive HVAC Insulation Services for Biopharmaceutical and Pharmaceutical Facilities

19th April 2025
Clinical Trials

Oracle Wins the Asia Pacific Biopharma Excellence Awards

21st March 2025
Americas

Thermo Fisher to acquire Solventum’s Purification & Filtration business for US$4.1bn

4th March 2025
Drug Development

Celonic Group Signs Long-Term Multi-Year Manufacturing Service Agreement with LINDIS Biotech for the Commercial Supply of Catumaxomab

4th March 2025
Next Post
Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22

Incyte Announces Plans to Initiate a Phase 3 Clinical Trial of Ruxolitinib as a Treatment for Patients with COVID-19 Associated Cytokine Storm

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In